Is Alector, Inc. (ALEC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 16.4% / 30% | 116.0% / 30% | 0.0% / 30% | 62.94% / 5% | ✗ NOT HALAL |
| DJIM | 16.4% / 33% | 116.0% / 33% | 0.0% / 33% | 62.94% / 5% | ✗ NOT HALAL |
| MSCI | 12.4% / 33% | 87.3% / 33% | 0.0% / 33% | 62.94% / 5% | ✗ NOT HALAL |
| S&P | 16.4% / 33% | 116.0% / 33% | 0.0% / 33% | 62.94% / 5% | ✗ NOT HALAL |
| FTSE | 12.4% / 33% | 87.3% / 33% | 0.0% / 50% | 62.94% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -587.5% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -181.6% | |
| Return on Assets (ROA) | -25.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$184M |
| Free Cash Flow | -$184M |
| Total Debt | $36M |
| Debt-to-Equity | 118.2 |
| Current Ratio | 3.8 |
| Total Assets | $293M |
Price & Trading
| Last Close | $2.12 |
| 50-Day MA | $2.05 |
| 200-Day MA | $1.96 |
| Avg Volume | 931K |
| Beta | 0.5 |
|
52-Week Range
$0.87
| |
About Alector, Inc. (ALEC)
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Alector, Inc. (ALEC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Alector, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Alector, Inc.'s debt ratio?
Alector, Inc.'s debt ratio is 16.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 12.4%.
What are Alector, Inc.'s key financial metrics?
Alector, Inc. has a market capitalization of $221M, and revenue of $21M. Return on equity stands at -181.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.